Citius Pharmaceuticals, Inc. (CTXR) financial statements (2021 and earlier)
Company profile
| Business Address |
11 COMMERCE DRIVE CRANFORD, NJ 07016 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 TTM | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | 9/30/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3 | 8 | 9 | 3 | 0 | 1 | |||
| Cash and cash equivalents | 3 | 8 | 9 | 3 | 0 | 1 | |||
| Receivables | 1 | ||||||||
| Prepaid expense | 0 | 0 | 0 | 0 | 1 | 0 | |||
| Total current assets: | 3 | 8 | 10 | 3 | 1 | 1 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1 | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Leveraged leases, net investment in leveraged leases disclosure, investment in leveraged leases | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 0 | 0 | 0 | 0 | 0 | ||||
| Intangible assets, net (including goodwill) | 2 | 2 | 2 | 2 | 2 | 0 | ✕ | ||
| Goodwill | 2 | 2 | 2 | 2 | 2 | ||||
| Intangible assets, net (excluding goodwill) | 0 | ||||||||
| Other undisclosed noncurrent assets | 18 | 18 | 19 | 19 | 19 | ||||
| Total noncurrent assets: | 22 | 21 | 21 | 21 | 21 | 0 | |||
| TOTAL ASSETS: | 25 | 29 | 31 | 24 | 22 | 1 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 3 | 4 | 3 | 2 | 3 | 1 | 0 | ||
| Accounts payable | 2 | 3 | 2 | 1 | 1 | 1 | 0 | ||
| Accrued liabilities | 0 | 0 | 0 | 1 | 1 | 0 | |||
| Employee-related liabilities | 1 | 1 | 1 | 1 | 1 | ||||
| Interest and dividends payable | 0 | 0 | 0 | 0 | 0 | ||||
| Debt | 0 | 0 | 0 | 0 | 0 | ||||
| Derivative instruments and hedges, liabilities | 2 | 1 | |||||||
| Due to related parties | 0 | 0 | 0 | ||||||
| Other undisclosed current liabilities | 1 | 0 | |||||||
| Total current liabilities: | 4 | 5 | 3 | 2 | 5 | 1 | 0 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1 | ||||||||
| Operating lease, liability | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Total noncurrent liabilities: | 1 | ||||||||
| Total liabilities: | 5 | 5 | 3 | 2 | 5 | 1 | 0 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 20 | 24 | 28 | 22 | 17 | (1) | (0) | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 80 | 80 | 68 | 50 | 34 | 8 | 0 | ||
| Accumulated deficit | (60) | (56) | (40) | (28) | (17) | (9) | |||
| Other undisclosed stockholders' equity attributable to parent | (0) | ||||||||
| Total stockholders' equity: | 20 | 24 | 28 | 22 | 17 | (1) | (0) | ||
| TOTAL LIABILITIES AND EQUITY: | 25 | 29 | 31 | 24 | 22 | 1 | |||
Income statement (P&L) ($ in millions)
| 12/31/2019 TTM | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | 9/30/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 0 | 0 | 1 | |||||
| Other operating income | 1 | |||||||
| Other income | 0 | ✕ | ||||||
| Cost of revenue (Cost of Goods and Services Sold) | (0) | (0) | ||||||
| Gross profit: | 0 | 0 | 1 | (0) | ||||
| Operating expenses | (16) | (16) | (14) | (10) | (7) | (3) | (0) | |
| Other undisclosed operating income (loss) | (0) | (0) | (1) | 0 | ||||
| Operating loss: | (16) | (16) | (14) | (10) | (7) | (3) | (0) | |
| Nonoperating income (expense) | 0 | 0 | 1 | (0) | (1) | 0 | ||
| Investment income, nonoperating | 0 | 0 | ||||||
| Debt instrument, convertible, beneficial conversion feature | 2 | 2 | ||||||
| Other nonoperating income | 0 | 0 | ||||||
| Interest and debt expense | (0) | (0) | 0 | (1) | (0) | (0) | (0) | |
| Loss from continuing operations before equity method investments, income taxes: | (16) | (16) | (12) | (11) | (8) | (3) | (0) | |
| Other undisclosed income (loss) from continuing operations before income taxes | 31 | 31 | (0) | 1 | 0 | 0 | ||
| Income (loss) before gain (loss) on sale of properties: | 15 | 16 | (13) | (10) | (8) | (3) | (0) | |
| Other undisclosed net loss | (31) | (31) | ||||||
| Net loss: | (16) | (16) | (13) | (10) | (8) | (3) | (0) | |
| Other undisclosed net loss attributable to parent | (0) | |||||||
| Net loss available to common stockholders, diluted: | (16) | (16) | (13) | (10) | (8) | (3) | (0) | |
Comprehensive Income ($ in millions)
| 12/31/2019 TTM | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | 9/30/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (16) | (16) | (13) | (10) | (8) | (3) | (0) | |
| Comprehensive loss, net of tax, attributable to parent: | (16) | (16) | (13) | (10) | (8) | (3) | (0) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.